Ofer Gonen - 18 Mar 2026 Form 3 Insider Report for MediWound Ltd. (MDWD)

Reporting relationship: Chief Executive Officer
Issuer ticker: MDWD
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 17:20:16 UTC
Prior SEC filing: 03 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Yaron Meyer, attorney-in-fact

Key filing fact

Ofer Gonen filed Form 3 for MediWound Ltd. (MDWD) on 18 Mar 2026.

Key facts

This page summarizes Ofer Gonen's Form 3 filing for MediWound Ltd. (MDWD).
0 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 18 Mar 2026, 17:20.

Change

Previous filing in this sequence was filed on 03 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001796468 Primary reporting owner

Gonen Ofer

Relationship: Chief Executive Officer
Address: C/O MEDIWOUND LTD., 42 HAYARKON STREET, YAVNE, ISRAEL
Signature: /s/ Yaron Meyer, attorney-in-fact
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDWD holding

Ordinary shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 22,137
Date: 18 Mar 2026
Ownership: Direct

MDWD holding

Ordinary shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 35,714
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

MDWD holding

Ordinary shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 11,784
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F2

MDWD holding

Ordinary shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,500
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F3

MDWD holding

Ordinary shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,900
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDWD holding Derivative

Series A Warrants

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 8,168
Exercise price: $13.48

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 85,714
Exercise price: $13.14
Footnotes: F5

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 86,000
Exercise price: $11.88
Footnotes: F6

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 94,273
Exercise price: $12.73
Footnotes: F7

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 68,000
Exercise price: $18.54
Footnotes: F8

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 71,000
Exercise price: $17.60
Footnotes: F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on June 7, 2022 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F2

The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F3

The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F4

The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F5

The options reported in this row were granted to the Reporting Person on June 7, 2022 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F6

The options reported in this row were granted to the Reporting Person on May 31, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F7

The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F8

The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F9

The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .